Abstract: A process for producing a crosslinked cellulose ether including the steps of (i) contacting at least one cellulose material with a mixture comprising (ia) at least one crosslinking agent and (ib) at least one alkalization reagent to form an activated cellulose material; and (ii) contacting the activated cellulose material of step (i) with at least one etherification reagent; wherein the at least one etherification reagent reacts with the activated cellulose material to form the crosslinked cellulose ether; and a crosslinked cellulose ether produced by the above process.

Abstract: The present disclosure describes GLP-1R modulating compounds that are useful for treating GLP-1R-mediated diseases or conditions.

Abstract: Disclosed are compounds and compositions for the activation or induction of expression of a pattern recognition receptor (e.g., STING, RIG-I, MDA5), and methods of use thereof.

Abstract: The present invention relates to new uses of a 5-HT4 receptor agonist, specifically Isopropyl-3-{5-[1-(3-methoxypropyl)piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole (Compound-1) or a pharmaceutically acceptable salts thereof, for the treatment of dementia due to menopause, senile dementia, cognitive deficits associated with schizophrenia, depression, chemotherapy-induced cognitive impairment, and behavioral and psychological symptoms of dementia such as apathy/indifference, agitation, aggression, depression, anxiety, irritability/lability, dysphoria, aberrant motor behavior, delusions, hallucinations, elation/euphoria, psychosis, disinhibition, sleep and night time behavior disorders or appetite and eating disorders. The present invention further provides use of the 5-HT4 receptor agonist in the manufacture of medicament intended for the treatment of the disorders described herein.

Abstract: Embodiments provided herein include methods, compositions, and uses of aromatic alcohols to increase the potency of antifungal agents.

Abstract: The present invention relates to new isoindolinone or isobenzofuranone substituted indoles and derivatives of formula (I) wherein the groups R1 to R7, R10 and n have the meanings given in the claims and specification, their use as inhibitors of RAS-family proteins and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.

Abstract: Provided herein are methods of treating ST-elevation myocardial infarction (STEMI) and diseases of the digestion system using ?-1,3/1,6-D-glucan derived from mycelium extract of Ganoderma lucidum. Methods of treating ST-elevation myocardial infarction (STEMI) and diseases of the digestion system using a polysaccharide comprising ?-1,3/1,6-D-glucan are also provided.

Abstract: A compound of formula (I), (IA) or formula (II) or a composition comprising the compound of formula (I), (IA) or formula (II) in association with a veterinarily acceptable carrier are described. A method of controlling helminths using same is described.

Abstract: The invention generally relates to an improved processes for the preparation of a cyclic dinucleotide which is useful as a STING agonist of the following formula (I), involving the use of compounds A and B.

Abstract: The present disclosure relates to the production of biomass from at least one plastic polymer. More specifically, the present disclosure relates to use of a feed for production of biomass, wherein larvae of the family Pyralidae or of the family Tenebrionidae are fed on a feed comprising at least one plastic polymer, a related use of increasing pupation in a population of larva.

Abstract: A method for producing an oligonucleotide, including a step of removing a temporary protecting group of a 5?-hydroxyl group by adding an acid to a protected oligonucleotide having a phosphorothioate (PS), phosphate (PO) or H-phosphonate moiety, and deacylating a by-product having an acylated 5?-hydroxyl group by solvolysis can complete a condensation reaction to improve a condensation yield, and can markedly reduce impurities such as single base deletion form (N-1mer) and the like.

Abstract: Hydrogel nanobeads include an ionically crosslinked sulfated polysaccharide biopolymer such as a carrageenan. In an embodiment, the hydrogel nanobeads comprise kappa carrageenan (?Cg) and a metal ion crosslinking agent. In an embodiment, the metal ion crosslinking agent includes a metal ion selected from the group consisting of Zn2+, Fe2+, Fe3+, and Ti3+. The hydrogel nanobeads can be used for removal of pollutants in wastewater.

Abstract: Provided are formulations of ivosidenib including a number of polymorphs. Further provided are formulations of ivosidenib containing a number of known impurities. Still further provided are stable compositions of ivosidenib.

Abstract: Allulose crystals are efficiently produced from an allulose syrup using seed crystals.

Abstract: Formulation of ectoparasiticidal and antibiotic “compositions into pharmaceutical compositions useful for the treatment of eyelid inflammation, in particular demodex related blepharitis and eye crusting.

Abstract: The present invention relates to nutritional compositions comprising 2?-Fucosyllactose (2?FL) for use in improving the gastrointestinal barrier. In particular, the present invention relates to improving gastrointestinal barrier in an infant, a young child or children aged above 3 years to 8 years.

Abstract: The present disclosure relates to compositions comprising mixtures of hydroxypropyl-?-cyclodextrin, wherein the compositions may be isomerically purified. The disclosure also relates to methods of isomerically purifying a mixture of hydroxypropyl-?-cyclodextrins.

Abstract: Disclosed herein are improved processes for making tagatose including the steps of converting F6P to T6P, catalyzed by a F6PE; and converting the T6P to tagatose, catalyzed by a T6PP, using enzymes with higher activities compared to F6PEs and T6PPs previously used in a process to produce tagatose.

Abstract: Among others, the present invention provides methods and compositions for controlling blood glucose or weight, including a combination of (i) a therapeutically effective amount of berberine (BBR), or a pharmaceutically acceptable salt, acid, ester, analog or derivative thereof, including dihydroberberine (DHB); and (ii) vitamin B12. The combination effectively ameliorates BBR or DHB side effects, including VB12 reduction, gastrointestinal discomfort, and slowed bowel movements, by promoting transcobalamin II receptors synthesis, decreasing homocysteine levels and maintaining intestinal balance, including short chain fatty acids content, gut microbiota diversity and richness.

Abstract: The present invention provides a composition comprising adenosine or adenosine triphosphate (ATP) acting as an absorption enhancer when combined with a nutritional material(s) such as nutrients, protein, peptides, vitamins, phytochemicals, minerals, fatty acids, or amino acids or a drug. Methods of administering ATP or adenosine to improve the bioavailability of a nutritional material(s) such as nutrients, protein, peptides, vitamins, phytochemicals, minerals, fatty acids, or amino acids or a drug are described.